Earnings summaries and quarterly performance for PRECISION BIOSCIENCES.
Executive leadership at PRECISION BIOSCIENCES.
Board of directors at PRECISION BIOSCIENCES.
Research analysts covering PRECISION BIOSCIENCES.
Recent press releases and 8-K filings for DTIL.
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants
DTIL
New Projects/Investments
- Precision BioSciences, Inc. (DTIL) announced an underwritten offering of 10,815,000 shares of common stock and accompanying warrants, along with pre-funded warrants to purchase up to 1,400,000 shares of common stock and accompanying warrants. The offering is expected to close on or about November 12, 2025.
- The combined offering price is $6.14 for common stock and warrants, and $6.139995 for pre-funded warrants and warrants. Each whole warrant has an exercise price of $7.25 per share and will expire five years following the date of issuance.
- The company anticipates gross proceeds of approximately $75 million and estimated net proceeds of approximately $70.0 million from the offering.
- Net proceeds will be used to fund ongoing and planned research and development, working capital, and general corporate purposes.
Nov 12, 2025, 2:12 PM
Precision BioSciences Reports Positive Clinical Data for HBV Program and Secures $75 Million in Funding
DTIL
New Projects/Investments
Guidance Update
- Precision BioSciences presented positive late-breaking data from its Eliminate B trial for PBG.001-HBV at AASLD, highlighting dose-dependent antiviral effects, a manageable safety profile, and the first clinical biopsy evidence of gene editing in HBV.
- The company anticipates that data from cohort three of the PBG.001-HBV trial indicates a near-term path towards stopping nucleos(t)ide analogs (nukes) and testing for a cure, with dosing for this cohort projected to conclude in Q1 2026.
- Precision BioSciences secured $75 million through a public offering, extending its operational runway through 2028 to fund the PBG.001-HBV program through Phase 2 and the PBG.001-DMD program through pivotal trials to BLA submission.
- The PBG.001-DMD program is on track for an IND filing by the end of 2025 and expects to dose its first patient in Q1 2026, with initial patient data anticipated by the end of 2026.
Nov 11, 2025, 1:00 PM
Precision BioSciences Provides Clinical Program Updates and Announces $75M Financing
DTIL
New Projects/Investments
Guidance Update
- Precision BioSciences announced a successful $75 million financing that extends its cash runway through 2028 to advance its lead programs, PBGENE-HBV and PBGENE-DMD.
- The company's wholly-owned PBGENE-HBV program for Chronic Hepatitis B has delivered 22 doses across 9 patients to date, demonstrating responses at all dose levels and an emerging path to expansion phase and Phase II earlier than anticipated.
- As of the October 31, 2025 data cutoff, all three patients in Cohort 3 of the PBGENE-HBV study at 0.8 mg/kg are showing deepening responses towards a benchmark for considering stopping NUCs.
- Precision BioSciences expects multiple clinical data readouts over the next 12-24 months, including initial PBGENE-HBV clinical data in 2025 and an IND filing for PBGENE-DMD in late 2025, with patient dosing projected for 2026.
Nov 11, 2025, 1:00 PM
Precision Biosciences Provides Clinical Update on HBV and DMD Programs, Announces $75 Million Public Offering
DTIL
Guidance Update
New Projects/Investments
- Precision Biosciences (DTIL) announced a public offering that raised $75,000,000, securing its cash and operational runway through 2028 to fund the Phase two HBV (ELIMINATE B trial) and the DMD pivotal to BLA submission.
- The ELIMINATE B trial for chronic hepatitis B (PBGene HBV) has demonstrated dose-dependent antiviral activity and improved durability across all three cohorts, with the 0.8 mg/kg dose in Cohort 3 showing a near-term path towards stopping NUCs and testing for cure.
- PBGene HBV has been well tolerated across all three cohorts with repeat administrations, with no dose-limiting toxicities observed and manageable, predictable adverse events in the ELIMINATE B study.
- First-ever clinical biopsy data from the ELIMINATE B trial revealed 28% editing (indel formation) in the viral DNA after two administrations at 0.4 mg/kg, providing proof of mechanism that PBGene HBV edits viral DNA in humans.
Nov 11, 2025, 1:00 PM
Precision BioSciences Provides Clinical Program Update and Financial Runway
DTIL
New Projects/Investments
Guidance Update
- Precision BioSciences (DTIL) announced a $75 million public offering to extend its operational runway through 2028, funding the PBG.001-HBV program through Phase 2 and the PBG.001-DMD program through BLA submission.
- The company's PBG.001-HBV program for chronic hepatitis B, in its Phase 1 Eliminate B trial, has demonstrated dose-dependent antiviral effects and a manageable safety profile with no dose-limiting toxicities, with cohort 3 data indicating a near-term path to Part 2 expansion.
- The PBG.001-DMD program for Duchenne muscular dystrophy is on track for an IND filing by the end of 2025 and is projected to begin clinical trials in Q1 2026, with a potential BLA filing in 2028.
- Biopsy data from the PBG.001-HBV trial provided proof of mechanism, showing 28% mutations introduced by Arcus in viral DNA.
Nov 11, 2025, 1:00 PM
Precision BioSciences Provides Clinical Updates and Announces $75 Million Public Offering
DTIL
New Projects/Investments
Guidance Update
- Precision BioSciences announced a $75 million public offering on 2025-11-10, securing its operational runway through 2028 to fund its PBGENE-HBV Phase II program and PBGENE-DMD program through BLA submission.
- In the PBGENE-HBV (Eliminate B trial) for chronic hepatitis B, no dose-limiting toxicities have been observed across 22 doses in cohorts up to 0.8 mg/kg.
- Biopsy data from the PBGENE-HBV trial demonstrated 28% mutations introduced by Arcus after two doses of 0.4 mg/kg, marking the first clinical biopsy evidence of gene editing in HBV.
- The PBGENE-DMD program for Duchenne muscular dystrophy is slated for an IND filing by the end of 2025 and clinical study initiation in Q1 2026, targeting a BLA filing in 2028.
Nov 11, 2025, 1:00 PM
Precision BioSciences Presents Positive Phase 1 PBGENE-HBV Data at AASLD
DTIL
New Projects/Investments
- Precision BioSciences, Inc. announced late-breaking Phase 1 PBGENE-HBV data from the ELIMINATE-B study, indicating the gene editing therapy was well-tolerated across doses of 0.2mg/kg, 0.4mg/kg, and 0.8mg/kg with no dose-limiting toxicities.
- The study demonstrated a dose-dependent antiviral response in all nine patients across 22 doses in the first three cohorts, with all three patients in the highest dose cohort (0.8 mg/kg) showing steep declines of HBsAg at day 14.
- Evidence of cumulative HBsAg declines was observed, including one patient in Cohort 1 showing a durable ~50% reduction at 9 months and Cohort 2 patients achieving reductions up to 66%.
- Paired biopsy data confirmed viral DNA gene editing in humans, directly correlating with observed HBsAg reductions, suggesting a potential path towards nucleos(t)ide withdrawal and testing for cure.
- The company expects to complete all administrations in Cohort 3 by Q1 2026 and plans to advance PBGENE-HBV into the Part 2 expansion phase of the ELIMINATE-B study.
Nov 10, 2025, 10:20 PM
Precision BioSciences Reports Q3 2025 Financial Results and Business Updates
DTIL
Earnings
Guidance Update
New Projects/Investments
- Precision BioSciences reported a net loss of $21.8 million, or ($1.84) per share, for the third quarter ended September 30, 2025, with total revenues of less than $0.1 million.
- As of September 30, 2025, the company held approximately $71.2 million in cash, cash equivalents, and restricted cash, and expects its cash runway to extend into the second half of 2027.
- In its PBGENE-HBV program, dosing commenced in Cohort 3 of the ELIMINATE-B trial, with additional data readouts planned for early 2026.
- For the PBGENE-DMD program, an Investigational New Drug (IND) filing is anticipated by the end of 2025, with Phase 1 initiation expected in the first half of 2026 and initial data in the second half of 2026.
Nov 3, 2025, 12:00 PM
Chardan Conference Highlights Advances in Gene Editing and Clinical Progress
DTIL
New Projects/Investments
Product Launch
- Precision Biosciences and eCure are advancing gene insertion therapies, with eCure reporting positive 10-month clinical data for its ornithine transcarbamylase (OTC) deficiency program using Precision's Arcus technology, demonstrating significant clinical improvements in a pediatric patient.
| Metric | At Dosing | 10 Months Post-Treatment |
|---|---|---|
| Patient Age | 6.5 months | N/A |
| Scavenger Medications | On standard of care | Discontinued within 3 months |
| Hyperammonemic Events/Crisis | Experienced | None |
| Ammonium Levels Reduction | N/A | ~50% |
| Liver Transplant List | On list | Off list |
- Precision Biosciences is also developing Arcus nuclease-based gene editing for hepatitis B, delivered via lipid nanoparticles (LNP), with initial clinical data showing good safety and antiviral activity (substantial S antigen reductions) in the lowest dose cohort.
- Companies like Seamless Therapeutics and Harborside are leveraging recombinase technology for gene integration, offering advantages for inserting large DNA fragments and targeting specific genomic safe harbors or endogenous promoters, which is crucial for treating diseases with multiple mutations and ensuring durable expression in growing tissues.
- The overall sentiment in the genetic medicine space is cautiously optimistic, with a strong desire for more clinical data and a focus on commercial potential and addressing unmet needs, with regulators showing flexibility and support for advanced therapies.
Oct 21, 2025, 1:30 PM
Precision Biosciences Provides Update on Arcus Gene Editing Platform and HBV Program
DTIL
New Projects/Investments
Product Launch
Guidance Update
- Precision Biosciences presented its proprietary Arcus gene editing platform, highlighting its differentiation from other technologies due to its compact size and single-protein simplicity.
- The company's lead program, PBG-HBV, is designed to achieve a complete cure for Hepatitis B by directly eliminating cccDNA and inactivating integrated HBV DNA, a distinct approach from current functional cure strategies.
- In the ongoing ILLUMINATE B Phase 1 study, Cohort 1 (0.2 mg/kg) demonstrated good tolerability and antiviral activity, with all three participants achieving 45% to almost 70% S antigen reduction. One participant sustained a 50% reduction in S antigen seven months post-treatment.
- Cohort 2 (0.4 mg/kg) has also shown good tolerability with repeat administrations, and Cohort 3 has been initiated.
- Precision Biosciences plans to share additional data from the ILLUMINATE B study at the upcoming AASLD Liver Meeting and will continue to optimize dosing schedules, potentially exploring shorter dosing intervals and higher dose levels.
Oct 21, 2025, 11:00 AM
Quarterly earnings call transcripts for PRECISION BIOSCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track PRECISION BIOSCIENCES's earnings for you
Get instant analysis when filings drop